Cardinal Health to offer MicroPhage's one-day antibiotic-resistance test to NA customers
This article was originally published in Clinica
Privately-held MicroPhage is to see its first product, an antibiotic susceptibility and resistance test, distributed to hospitals and healthcare centres across North America, after striking a deal with multi-billion-dollar healthcare products and services provider Cardinal Health. The latter will be the exclusive distributor of the recently FDA-cleared KeyPath MRSA/MSSA blood culture test – BT, which provides same-day results to confirm the presence of Staphylococcus aureus and identify whether the bacteria is either methicillin-resistant or –susceptible. Additionally, under the agreement, Cardinal Health will have exclusive rights to other products in Longmont, Colorado-based MicroPhage's pipeline which test blood culture specimens for S aureus. In exchange for these rights, Cardinal will invest in Cardinal for an undisclosed amount to help fund the development and commercialisation of these new products.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.